Literature DB >> 23271036

[Chromogranin A and neuroendocrine tumors].

José Ángel Díaz Pérez1, Maria Currás Freixes.   

Abstract

Chromogranin A (CgA) is the most abundant granin in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). As a tumor marker is moderately sensitive and nonspecific. Despite the limitations of testing methods, which require careful interpretation, especially in the case of gastrinomas, patients treated with somatostatin analogues, and poorly differentiated tumors, it is the best tumor marker in GEP-NETs and may be of value in other tumors with neuroendocrine differentiation. CgA may be used as a marker in blood or tissue samples through immunohistochemical techniques. CgA levels correlate with tumor burden and extension and may be used for diagnosis and monitoring of GEP-NETs, especially midgut carcinoids and endocrine pancreatic tumors. It is also useful as a prognostic marker for detection of recurrence and monitoring of response to different treatments.
Copyright © 2012 SEEN. Published by Elsevier Espana. All rights reserved.

Entities:  

Keywords:  Chromogranin A; Cromogranina A; Gastrinoma; Gastroenteropancreatic neuroendocrine tumors; Tumores neuroendocrinos gastroenteropancreáticos

Mesh:

Substances:

Year:  2012        PMID: 23271036     DOI: 10.1016/j.endonu.2012.10.003

Source DB:  PubMed          Journal:  Endocrinol Nutr        ISSN: 1575-0922


  4 in total

1.  Use of full-dose contrast-enhanced CT for extrahepatic staging using Gallium-68-DOTATATE PET/CT in patients with neuroendocrine tumors.

Authors:  Jonas Apitzsch; Frederik Anton Verburg; Felix Mottaghy; Alexander Heinzel
Journal:  Diagn Interv Radiol       Date:  2021-07       Impact factor: 2.630

2.  Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.

Authors:  Meng Zhang; Ping Zhao; Xiaodan Shi; Ahong Zhao; Lianfeng Zhang; Lin Zhou
Journal:  BMC Endocr Disord       Date:  2017-07-13       Impact factor: 2.763

3.  Biological function and clinical relevance of chromogranin A and derived peptides.

Authors:  Maria Angela D'amico; Barbara Ghinassi; Pascal Izzicupo; Lamberto Manzoli; A Di Baldassarre
Journal:  Endocr Connect       Date:  2014-04-29       Impact factor: 3.335

4.  A novel bioengineered fragment peptide of Vasostatin-1 exerts smooth muscle pharmacological activities and anti-angiogenic effects via blocking VEGFR signalling pathway.

Authors:  Ran Wei; Qiushuang Wu; Nana Ai; Lei Wang; Mei Zhou; Chris Shaw; Tianbao Chen; Richard Dequan Ye; Wei Ge; Shirley W I Siu; Hang Fai Kwok
Journal:  Comput Struct Biotechnol J       Date:  2021-05-03       Impact factor: 7.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.